Adoption of electronic health records in UK hospitals: lessons from the USA

are still professionals and companies with genuine commitment to patients with rare diseases such as phenylketonuria. A strong movement is working towards centres of expertise for the treatment of patients with rare diseases, and opportunities exist to allow new and existing pharmaceutical companies to develop orphan drugs. Such developments will further improve treatment and outcomes in future generations of patients, although the risk remains that drug development might lead to a monopoly situation for any successfully developed products.

[1]  A. Sheikh,et al.  A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis , 2012, The Lancet.

[2]  G. Sedvall,et al.  Amino Acids in Plasma and CSF and Monoamine Metabolites in CSF: Interrelationship in Healthy Subjects , 1984, Journal of neurochemistry.

[3]  P. Burgard,et al.  The truth of treating patients with phenylketonuria after childhood: The need for a new guideline , 2008, Journal of Inherited Metabolic Disease.

[4]  J. Hoskins,et al.  ENZYMATIC CONTROL OF PHENYLALANINE INTAKE IN PHENYLKETONURIA , 1980, The Lancet.

[5]  Dimitra I. Petrakaki,et al.  Implementation and adoption of nationwide electronic health records in secondary care in England: final qualitative results from a prospective national evaluation in 'early adopter' hospitals , 2011 .

[6]  Farzad Mostashari,et al.  Adoption of electronic health records grows rapidly, but fewer than half of US hospitals had at least a basic system in 2012. , 2013, Health affairs.

[7]  G. Levi,et al.  Executive function impairment in early-treated PKU subjects with normal mental development , 2004, Journal of Inherited Metabolic Disease.

[8]  D. Blumenthal,et al.  The "meaningful use" regulation for electronic health records. , 2010, The New England journal of medicine.

[9]  G. Enns,et al.  Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence. , 2010, Molecular genetics and metabolism.

[10]  S. Kure,et al.  Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. , 1999, The Journal of pediatrics.

[11]  J. Vockley,et al.  Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial , 2014, The Lancet.

[12]  Jennifer Dixon,et al.  Health-care reforms in the USA and England: areas for useful learning , 2012, The Lancet.

[13]  H. Möller,et al.  Neurocognitive functioning in adults with phenylketonuria: results of a long term study. , 2013, Molecular genetics and metabolism.

[14]  A. Roscher,et al.  Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. , 2002, The New England journal of medicine.

[15]  Y. Okano,et al.  Optimal serum phenylalanine for adult patients with phenylketonuria. , 2013, Molecular genetics and metabolism.

[16]  D. Blumenthal.  Wiring the health system--origins and provisions of a new federal program. , 2011, The New England journal of medicine.